Gentronix was founded in 1999 as a spin-out from The University of Manchester to commercialise patented new technology for the early identification of genotoxic carcinogens. This technology is now available in a kit format, known as GreenScreen HC, for the early genotoxicity screening of new drug compounds.
Developed in a simple microplate format requiring less than 1mg of compound, the assay is easily automated using standard laboratory equipment. Published results and trial data demonstrate a unique combination of exceptionally high sensitivity and specificity, making GreenScreen HC the first in vitro mammalian cell assay truly suitable for early candidate screening.
No reviews to display
24 Apr 2013
25 Aug 2011
Gentronix Further Expands Early Genotoxicity Screening Capability with Introduction of Ames MPF™ Screening Service
30 Mar 2011
ADVANCELL partners with Gentronix to Offer Genotoxicity Screening Assays to the Cosmetics and Personal Care Sector
09 Dec 2010
21 Sep 2010